TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthcare personnel (HCP) who have direct contact with patients, including dentists and other dental health personnel~* Enrolled in Scott \& White Healthcare or Kaiser Permanente health network for at least one month~* Aged 18-64 years for newly enrolled participants~* Aged 18-65 years for participants who were originally enrolled in year one of the study and return for year 2~* Available and willing to participate in study follow-up through the end of the 2019-2020 influenza season (i.e. at least approximately 18 months if enrolled during season 1 or 6 months if enrolled during season 2)~* Received an egg-based standard dose influenza vaccine during the 2018-2019 influenza season (for participants enrolled for the first-time during year two)~Exclusion Criteria:~* Already received an influenza vaccine during the current influenza season~* Previous hypersensitivity reaction to the study vaccines as reported by the subject~* Received any vaccine in the 4 weeks prior to the first study visit or plans to receive a vaccine (other than influenza vaccine provided through the study protocol) in the 4 weeks following the first study visit~* Currently participating in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication), or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive an experimental agent during participation in this study~* Any condition that the principle investigator (PI) believes may interfere with successful completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Flublok (Recombinant) (Type: ACTIVE_COMPARATOR): Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
- Flucelvax (Cell-based) (Type: ACTIVE_COMPARATOR): Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
- Fluarix (Egg-based) (Type: ACTIVE_COMPARATOR): Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
- Fluzone (Egg-based) (Type: ACTIVE_COMPARATOR): Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
- Fluzone (Egg-based) High-Dose (Type: ACTIVE_COMPARATOR): Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recovery and Analgesia After Surgery for Gynecological Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with gynecological cancer (suspected or verified) planned for explorative laparotomy through a middle-line incision with a curative purpose.~* WHO performance status \< 2.~* American Society of Anesthesiologists class 1-2.~* Women that understand and can express themselves in Swedish.~* Women that after verbal and written information accept participation in the study and have signed an informed consent.~Exclusion Criteria:~* Women where surgery is expected to include part/s, other than the abdominal surgery, where intrathecal or epidural analgesia is not expected to be effective~* Women with contra indications for intrathecal or epidural anesthesia.~* Women who are physically disabled and therefore nor expected to be mobilized on the day after surgery in the same way as non-disabled.~* Women with a mental retardation that makes it impossible to fill in the relevant questionnaires or makes it impossible to understand the meaning of participation, or if it is ethically doubtful to include the woman.~* Women with psychiatric or mental disorder that according to the responsible physician makes it unsuitable to participate in the study .

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Epidural analgesia (Type: ACTIVE_COMPARATOR): The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
- Intrathecal analgesia (Type: EXPERIMENTAL): The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* STEMI ≤ 12 hours (or STEMI equivalent).~* No contra - indications for primary PCI.~* No contra - indications for abciximab.~* Informed consent from the patient.~Exclusion Criteria:~* Contra - indication for primary PCI: History of peripheral/coronary artery disease that is inaccessible for angiography or PCI.~* Contra - indications for GPI: Ongoing bleeding, bleeding diathesis, cerebrovascular accident \< 6 months, major surgery/trauma \< 6 months, platelet count \< 100.000 mm3 , intracranial arteriovenous malformation or neoplasm, malignant hypertension, INR \>1.5, severe hepatic dysfunction~* Contra - indications for clopidogrel:~  * Severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or intracranial bleeding.~ * Thrombolytic therapy \< 24 hours.~ * Therapy with GPI \< 24 hours.~ * Anticoagulation therapy.~* Co - morbid conditions with a predictable fatal outcome in the short run.~* No informed consent: refusal, coma, artificial respiration, impaired mentation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bare metal stent (BMS) (Type: ACTIVE_COMPARATOR): None
- Drug eluting stent (DES) (Type: ACTIVE_COMPARATOR): None
- Abciximab (Type: ACTIVE_COMPARATOR): None
- No abciximab (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Successfully implanted BIOTRONIK CRT system, including a Corox BP LV lead, from 7-180 days prior to enrollment~* Able to understand the nature of the registry and give informed consent~* Available for follow-up visits on a regular basis at the investigational site~* Age greater than or equal to 18 years~Exclusion Criteria:~* Enrolled in any IDE clinical study~* Planned cardiac surgical procedures or interventional measures within the next 6 months~* Expected to receive a heart transplant within 1 year~* Life expectancy less than 1 year~* Presence of another life-threatening, underlying illness separate from their cardiac disorder~* Pregnancy~* Inability to provide date of implant, devices implanted, age, gender, and whether the patient experienced any protocol-defined adverse events since implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Data Collection Group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Treatment naïve and treatment experienced patients (prior relapse, interferon intolerant, and \[allowed in Cohort A only\] prior partial response).~2. Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.~3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver stiffness of =13 kPa on fibroscan.~Exclusion criteria:~1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined diagnosed by genotypic testing at screening~2. Liver disease due to causes other than chronic HCV infection which may include but is not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.~3. HIV infection~4. Patients who have been previously treated with an investigational or approved DAA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- cohort A CPA (Type: EXPERIMENTAL): Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
- cohort A CPB (Type: EXPERIMENTAL): Cohort B CPB BI 207127/QD Faldaprevir Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated, histologically confirmed mantle cell lymphoma.~* Measurable or evaluable disease.~* All stages are eligible.~* Age \> 18 years.~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.~* Adequate hepatic function:~  * Bilirubin \< 3 mg/dL.~ * Transaminases (SGOT and/or SGPT) \< than 2.5 times the upper limit of normal for the institution, unless due to lymphomatous involvement.~* Serum creatinine \< 1.5 mg/Dl.~* Ability to give informed consent.~* Women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.~* Life expectancy greater than 6 months.~Exclusion Criteria:~* Previous chemotherapy, immunotherapy or radiotherapy for this lymphoma~* Concurrent active malignancies, with the exception of in situ carcinoma of the cervix and basal cell carcinoma of the skin.~* Grade 3 or 4 cardiac failure and/or ejection fraction \< 50.~* Psychological, familial, sociological or geographical conditions that do not permit treatment and/or medical follow-up required to comply with the study protocol.~* Patients with a known history of HIV or AIDS~* Presence of hepatitis or hepatitis B virus (HBV) infection~* Pregnant or breast-feeding women.~* Central nervous system (CNS) involvement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-MACLO-IVAM-T (Type: EXPERIMENTAL): Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Obese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* BMI must be greater than 27 and less than 40~* Treated Type 2 Diabetes on single therapy treatment for at least 1 year~* Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women \> or = to 18 years of age meeting Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, currently experiencing a manic or mixed episode with a history of one or more manic or mixed episodes or sufficient severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1 (Type: PLACEBO_COMPARATOR): /Active Comparator
- A2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mother's Gift Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mothers from 18 to 14 years of age in the third trimester of pregnancy,~* with normal medical and obstetric history,~* who plan to deliver their infant in Dhaka city and remain there for 12m~Exclusion Criteria:~* Maternal history of systemic disease,~* Maternal history of previous complicated pregnancies, preterm delivery, abortions, or birth with congenital anomalies.~* Maternal hypersensitivity to any vaccination, or~* Maternal receipt of pneumococcal vaccine in the last 3 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing KIM to TVT Exact Sling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women greater than or equal to 21 years based on medical chart review~* Diagnosis of SUI or mixed urinary incontinence based on medical chart review~* Objective evidence of SUI as indicated by positive cough stress test or urodynamic stress incontinence during urodynamic testing within the last year prior to enrollment. Medical chart will be reviewed.~* Planning surgery for SUI with/without pelvic organ prolapse (POP) surgery~Exclusion Criteria:~* Current pregnancy, desire for future childbearing, less than or equal to 12 months postpartum at the time of enrollment~* Prior history of surgery for SUI based on medical chart review~* Bladder capacity \<200 mL on Urodynamic testing or post-void residual (PVR) \>150 mL on urodynamic testing or bladder scan.~* Non-ambulatory~* Current genitourinary fistula or urethral diverticulum based on pre-operative exam in the medical chart.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Gynecare TVT Exact sling (Type: ACTIVE_COMPARATOR): Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
- Neomedic KIM sling (Type: ACTIVE_COMPARATOR): Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has multicentric Castleman's disease~* Have previously been enrolled in Study C0328T03 or CNTO328MCD2001 (either treatment arm)~* Have had their last administration of study treatment (siltuximab or placebo) less than 6 weeks (window of plus 2 weeks) prior to first dose~* Patients must not have had disease progression while receiving siltuximab. For those patients originally assigned to placebo in the CNTO328MCD2001 study, patients who have received less than 4 months of siltuximab following crossover will also be eligible~* Have adequate clinical laboratory parameters within 2 weeks prior to the first dose of siltuximab for this study~Exclusion Criteria:~* Unmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab study~* Vaccination with live, attenuated vaccines within 4 weeks of first dose of this study~* Known unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siltuximab (Type: EXPERIMENTAL): Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Rabies Vaccine Immunization in Primary School Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Male and female 5-8 years old school children will be included in the study if:~* Their parents or legal guardians have given the written informed consent prior to study entry;~* They are in good health at time of study entry as determined by medical history, physical examination and clinical judgment of the investigator;~* They are available for all the visits scheduled in the study.~Exclusion criteria:~Subjects are not to be enrolled into the study if:~* They have a history of rabies immunization;~* They have an acute infectious disease at the time of study entry;~* They are under treatment with parenteral and/or oral steroids, immunosuppressive drugs, phenytoin or other specific anti-inflammatory drugs, or have taken chloroquine during the two month period before enrolment;~* They have a known immunodeficiency or an autoimmune disease;~* They have a known hypersensitivity to neomycin, tetracycline or amphotericin-B;~* They have planned surgery during the first study period (49 days);~* They are participating in any other trial of an investigational agent;~* They have any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives.~* The family plans to leave the area of the study site before the end of the study period.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- 2 primary ID doses (Type: EXPERIMENTAL): two doses of rabies vaccines given intradermally on days 0 and 28
- 3 primary ID doses (Type: EXPERIMENTAL): three doses of rabies vaccines given intradermally on days 0, 7, and 28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete